Read by QxMD icon Read

European Journal of Clinical Pharmacology

Andreea Farcas, Noemi Beatrix Bulik, Andreea Popa, Agatha Mensah Achampong, Camelia Bucsa, Cristina Mogosan
No abstract text is available yet for this article.
November 10, 2018: European Journal of Clinical Pharmacology
Reetta Kettunen, Heidi Taipale, Anna-Maija Tolppanen, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen, Marjaana Koponen
PURPOSE: To study how long antidepressants initiated after diagnoses of Alzheimer's disease (AD) were used and factors associated with discontinuation of use among persons with Alzheimer's disease (AD). In addition, differences in duration of use between the antidepressants groups were compared. METHODS: Register-based Medication use and Alzheimer's disease (MEDALZ) cohort included 70,718 community-dwelling people with AD who were diagnosed during the years 2005-2011...
November 9, 2018: European Journal of Clinical Pharmacology
Chanan Shaul, Simcha Blotnick, Liat Deutsch, Gilad Rosenberg, Yoseph Caraco
BACKGROUND: The initial rise in INR following warfarin is attributed to rapid decline in coagulation factor VII (F7). The R353Q polymorphism in F7 accounts for approximately 1/3 of the variability in F7 activity (FVIIc). OBJECTIVE: Evaluate the role of R353Q in the initial response to warfarin. METHODS: Twenty-eight healthy, males, carrying CYP2C9*1/*1 (n = 14), CYP2C9*1/*2 (n = 4) or CYP2C9*1/*3 (n = 10) genotypes, received single 20 mg warfarin...
November 9, 2018: European Journal of Clinical Pharmacology
Natasa Gisev, Sallie-Anne Pearson, Briony Larance, Sarah Larney, Bianca Blanch, Louisa Degenhardt
PURPOSE: Although guidelines caution against initiation of transdermal (TD) fentanyl among those who are opioid naïve, there is concern that not all people receive adequate prior opioid exposure. This study examined the percentage of people who are opioid naïve at the time of TD fentanyl initiation in Australia; strengths initiated; and characteristics associated with being opioid naïve. METHODS: This is a national retrospective cohort study derived from a 10% sample of Pharmaceutical Benefits Scheme concessional beneficiaries initiating TD fentanyl between 29 September 2009-31 December 2013...
November 3, 2018: European Journal of Clinical Pharmacology
Jonas Forsman, Thomas Masterman, Johan Ahlner, Göran Isacsson, Anna Karin Hedström
PURPOSE: We endeavored to investigate whether previous findings of an association between antemortem exposure to selective serotonin re-uptake inhibitors (SSRI) and method of suicide could be replicated. METHODS: Using the Swedish National Board of Forensic Medicine's toxicology database and the Swedish National Board of Health and Welfare's national registries of causes of death and prescriptions, 10,002 incidents of suicide were retrieved. Risks of violent suicide conferred by SSRIs, expressed as odds ratios (ORs) with 95% confidence intervals (CIs), were estimated using logistic regression...
November 3, 2018: European Journal of Clinical Pharmacology
Pan Chen, Xuan Xu, Longshan Liu, Jingjing Wu, Jingjie Li, Qian Fu, Jie Chen, Changxi Wang
PURPOSE: Mizoribine (MZR) is an immunosuppressive agent with extensive inter-individual differences in pharmacokinetics (PK). Here, we investigated the PK characteristics of MZR in renal transplant recipients and gave equations for prediction of some critical PK parameters. METHODS: A total of 40 renal transplant recipients participated in this prospective study and were administered MZR orally twice daily in the range of 1.1-8.9 mg kg-1  day-1 . Steady-state concentrations of MZR were detected before (0 h) and 0...
November 1, 2018: European Journal of Clinical Pharmacology
Marta Polkowska, Paweł Ekk-Cierniakowski, Edyta Czepielewska, Małgorzata Kozłowska-Wojciechowska
PURPOSE: In the management of melanoma, BRAF inhibitors yield fast disease control; however, the duration of response does not last very long. Ipilimumab-an anti-CTLA4 antibody on the other hand-provides longer-lasting results of treatment but achieves less favorable responses. The aim of this study was to assess the efficacy and safety of novel drugs for advanced melanoma in daily routine practice. METHODS: A retrospective observational study was conducted on all Polish patients (1170 patients), diagnosed with advanced metastatic melanoma, treated with the following drugs: vemurafenib, dabrafenib, and ipilimumab...
November 1, 2018: European Journal of Clinical Pharmacology
Yushi Kashihara, Yui Terao, Kensaku Yoda, Takeshi Hirota, Toshio Kubota, Miyuki Kimura, Shunji Matsuki, Masaaki Hirakawa, Shin Irie, Ichiro Ieiri
BACKGROUND: Magnesium oxide (MgO) is often co-prescribed with L-dopa/carbidopa (LDCD) to improve constipation in Parkinson's disease patients. The mixing of L-dopa and MgO has been shown to degrade L-dopa; however, there is no interaction study on humans. We proposed mechanisms for the interaction between LDCD and MgO and conducted pharmacokinetic studies on rats and humans. To assess pharmacodynamic changes with the MgO treatment, we applied a model-based meta-analysis (MBMA). METHODS: The effects of MgO on the stabilities of L-dopa and carbidopa were evaluated in in vitro studies...
October 31, 2018: European Journal of Clinical Pharmacology
Qiuyi Ji, Qing Xu, Zi Wang, Xiaoye Li, Qianzhou Lv
PURPOSE: The purpose of this study was to analyze the association between bleeding events and coagulation assays including activated partial thromboplastin time (APTT) and prothrombin time (PT), and to determine the risk factors for bleeding in Chinese patients with non-valvular atrial fibrillation (NVAF) receiving dabigatran. METHODS: We conducted a retrospective cohort study including NVAF patients receiving dabigatran 110 mg twice daily between March 2016 and November 2017...
October 30, 2018: European Journal of Clinical Pharmacology
Florent De Bruyne, Arnaud Ponçon, Joris Giai, Xavier Dode, David Darmon, Cyrille Colin, François Gueyffier, Laurent Letrilliart
PURPOSE: The prescription in International Nonproprietary Names (INN) is a legal obligation for all physicians in France since January 2015. The objective of this study was to analyze the frequency and main factors of INN drug prescribing in general practice. METHODS: Multicenter cross-sectional study conducted with 11 interns acting as observers of 23 GP trainers between November 2015 and January 2016. Two evaluators analyzed all GPs' drug prescriptions to identify INN or brand name prescriptions...
October 27, 2018: European Journal of Clinical Pharmacology
Manuela Vay, Kathrin I Foerster, Mazyar Mahmoudi, Jessica Seeßle, Gerd Mikus
No abstract text is available yet for this article.
October 22, 2018: European Journal of Clinical Pharmacology
Christina Raae Hansen, Stephen Byrne, Denis O'Mahony, Patricia M Kearney, Laura J Sahm
PURPOSE: Older people are at risk of potentially inappropriate prescribing (PIP) due to polypharmacy arising from multi-morbidity. Despite available explicit criteria to reduce PIP, it is highly prevalent. Whilst community pharmacists have the required knowledge to help reduce PIP, they are not currently engaged with the problem. This study explores the views of community pharmacists on their potential involvement in reducing PIP and determines the challenges to its implementation. METHODS: Semi-structured interviews with pharmacists working in community pharmacies in Ireland...
October 20, 2018: European Journal of Clinical Pharmacology
Matthew P Kosloski, Haoyu Wang, David Pugatch, Federico J Mensa, Edward Gane, Eric Lawitz, Thomas C Marbury, Richard A Preston, Jens Kort, Wei Liu
PURPOSE: This study characterized the effects of hepatic impairment on the pharmacokinetics and safety of glecaprevir and pibrentasvir, two direct-acting antivirals used for treatment of chronic HCV infection. METHODS: HCV-negative subjects with normal hepatic function, or with mild (Child-Pugh [CP]-A), moderate (CP-B), or severe (CP-C) hepatic impairment received single doses of pibrentasvir 120 mg alone or with glecaprevir 200 mg or 300 mg (n = 6/functional group/dose)...
October 19, 2018: European Journal of Clinical Pharmacology
Maria Adrover-Rigo, Maria-Dolores Fraga-Fuentes, Francesc Puigventos-Latorre, Iciar Martinez-Lopez
PURPOSE: To summarize literature specific to therapeutic interchange (TI) focusing on methodological approaches in order to develop a list of steps that healthcare facilities can consult when developing pharmacotherapeutic interchange guidelines (PTIGs) in hospitals and primary care centers. METHODS: A search was conducted in PreMEDLINE, Medline, EMBASE, PsycINFO, and the Cochrane Library up to and including December 2015. PRISMA guidelines were used. The inclusion criteria were articles published on TI: methodology, implementation, guidelines, and position statements of scientific societies...
October 19, 2018: European Journal of Clinical Pharmacology
Léa Hoisnard, Brigitte Santos-Eggimann, Pauline Chauvin, Anne Hiance-Delahaye, Marie Herr
PURPOSE: This study assessed the level of knowledge among community-dwelling older individuals about the purpose of medications and the characteristics that influenced that knowledge. We focused on drugs frequently used and/or often involved in iatrogenic events. METHODS: This cross-sectional survey included 2690 community-dwelling older adults, aged 68 years and above, who reported using at least one drug of interest, in the canton of Vaud, Switzerland. Participants reported drugs that they currently used and described their purpose...
October 17, 2018: European Journal of Clinical Pharmacology
Dena Firouzabadi, Negar Firouzabadi, Kiana Kalani, Kamyar Zomorrodian, Elham Shirazi Tehrani
PURPOSE: Heterotrimeric guanine nucleotide-binding proteins (G proteins) are a major group of human genome membrane protein receptors. Genetic variation in the β3 subunit (GNβ3) associated with gene splicing and increased activity is associated with major depressive disorder (MDD). However, the effect of G-350A GNβ3 genetic polymorphism and therapeutic outcome of selective serotonin reuptake inhibitors (SSRIs) in MDD has not yet been studied. METHOD: One hundred newly diagnosed MDD patients were treated with sertraline for 6 weeks...
October 15, 2018: European Journal of Clinical Pharmacology
Nawal Farhat, Nisrine Haddad, James Crispo, Nicholas Birkett, Doug McNair, Franco Momoli, Shi-Wu Wen, Donald R Mattison, Daniel Krewski
PURPOSE: The US Food and Drug Administration (FDA) issued three safety announcements between January 2009 and October 2010 warning against concomitant use of clopidogrel and proton pump inhibitors (PPIs) due to a potential drug-drug interaction that may attenuate clopidogrel's antiplatelet activity. This primary objective of this study was to examine trends in concomitant clopidogrel/PPI use among acute coronary syndrome (ACS) inpatients in the US between 2000 and 2016, in relation to the FDA safety communications...
October 15, 2018: European Journal of Clinical Pharmacology
Pär Parén, Annika Rosengren, Tatiana Zverkova Sandström, Maria Schaufelberger
PURPOSE: Loop diuretics are recommended to treat congestive symptoms in patients with heart failure. However, observational studies have indicated that loop diuretic treatment in heart failure is associated with increased mortality. Therefore, loop diuretic discontinuation or dose reduction, when clinically possible, is recommended. Our aim was to study nationwide temporal trends in loop diuretic treatment from 2005 to 2014 in real-life patients with chronic heart failure. METHODS: Data from the nationwide Swedish National Patient, Prescribed Drug and Cause of Death Registers were linked...
October 15, 2018: European Journal of Clinical Pharmacology
Nazanin Falconer, Michael Barras, Jennifer Martin, Neil Cottrell
PURPOSE: The multiplicity in terms and definitions of medication-related harm has been a long-standing challenge for health researchers, clinicians, and regulatory bodies. The purpose of this narrative review was to report the diversity of terms; compare definitions, classifications, and models describing medication harm; and suggest which may be useful in both clinical practice and the research setting. METHODS: A narrative review of key studies defining and/or classifying medication harm terminology was undertaken...
October 11, 2018: European Journal of Clinical Pharmacology
Tomáš Bolek, Matej Samoš, Ingrid Škorňová, Lucia Stančiaková, Barbora Korpallová, Peter Galajda, Ján Staško, Peter Kubisz, Marián Mokán
No abstract text is available yet for this article.
October 9, 2018: European Journal of Clinical Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"